Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests

World Journal of Gastroenterology

Volumn 20, Issue 12, 2014, Pages 3343-3349

  Wu, Jeng Yih ^a,c   Wang, Sophie S W ^b   Lee, Yi Chern ^b   Yamaoka, Yoshio ^d   Graham, David Y ^d   Jan, Chang Ming ^b   Wang, Wen Ming ^a,b,c   Wu, Deng Chyang ^b,c,e  

^a KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Clarithro mycin resistance; Helicobacter pylori; Polymerase chain reaction restriction fragment length polymorphism; String test

Indexed keywords

CAGA PROTEIN; CLARITHROMYCIN; GENOMIC DNA; RESTRICTION ENDONUCLEASE; RIBOSOME RNA; RNA 23S; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE ERADICATION; ENDOSCOPY; GENE MUTATION; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NONHUMAN; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; RAPID UREASE TEST; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY AND SPECIFICITY; STRING SIGN; DRUG EFFECTS; GENETICS; HELICOBACTER INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MUTATION;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; ENDOSCOPY; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIOLOGICAL TECHNIQUES; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RNA, RIBOSOMAL, 23S;

EID: 84896959933     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i12.3343     Document Type: Article

References (44)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315 [PMID: 6145023 DOI: 10.1016/ S0140-6736(84)91816-6]
2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helico-bacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-69 [PMID: 8007082 DOI: 10.1001/jama.272.1.65]
3. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helico-bacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 Suppl 2: 59-69 [PMID: 8547530]
4. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-1176 [PMID: 1682595 DOI: 10.1016/0140-6736(91)92035-Z]
5. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helico-bacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 1998; 115: 642-648 [PMID: 9721161 DOI: 10.1016/S0016-5085(98)70143-X]
6. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241 [PMID: 7715068]
7. Handa O, Naito Y, Yoshikawa T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep 2011; 16: 1-7 [PMID: 21605492 DOI: 10.1179/174329211X1296 8219310756]
8. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ch-ing CK, Chen JS. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194 [PMID: 14722144 DOI: 10.1001/jama.291.2.187]
9. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705-708 [PMID: 1558340 DOI: 10.7326/0003-4819-116-9-7 05]
10. Graham DY. Evolution of concepts regarding Helicobacter pylori: from a cause of gastritis to a public health problem. Am J Gastroenterol 1994; 89: 469-472 [PMID: 8147345]
11. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu BS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su IJ, Whang-Peng J, Cheng AL. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005; 97: 1345-1353 [PMID: 16174856 DOI: 10.1093/jnci/ dji277]
12. Park HS, Kim YJ, Yang WI, Suh CO, Lee YC. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 2010; 16: 2158-2162 [PMID: 20440857 DOI: 10.3748/wjg.v16.i17.2158]
13. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Heli-cobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
14. Gao XZ, Qiao XL, Song WC, Wang XF, Liu F. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol 2010; 16: 4357-4362 [PMID: 20818821 DOI: 10.3748/wjg.v16. i34.4357]
15. Molina-Infante J, Romano M, Fernandez-Bermejo M, Fed-erico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-128.e1 [PMID: 23562754]
16. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 14-day triple, 5-day concomitant, and 10-day sequential therapies for He-licobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378: 507-514 [PMID: 21777974 DOI: 10.1016/S0140-6736(11)60825-8]
17. Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-325 [PMID: 20054285]
18. Nishizawa T, Suzuki H, Suzuki M, Takahashi M, Hibi T. Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. J Clin Biochem Nutr 2012; 51: 114-116 [PMID: 22962528 DOI: 10.3164/jcbn. D-11-00029R1]
19. Mégraud F, Lehn N, Lind T, Bayerdörffer E, O'Morain C, Spiller R, Unge P, van Zanten SV, Wrangstadh M, Burman CF. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-2752 [PMID: 10543758]
20. Sun QJ, Liang X, Zheng Q, Gu WQ, Liu WZ, Xiao SD, Lu H. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. World J Gastroenterol 2010; 16: 5118-5121 [PMID: 20976850 DOI: 10.3748/wjg.v16.i40.5118]
21. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]
22. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-186.e3; Discussion e12-3 [PMID: 23751282]
23. Taylor DE, Ge Z, Purych D, Lo T, Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother 1997; 41: 2621-2628 [PMID: 9420030]
24. Occhialini A, Urdaci M, Doucet-Populaire F, Bébéar CM, Lamouliatte H, Mégraud F. Macrolide resistance in Helico-bacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Che-mother 1997; 41: 2724-2728 [PMID: 9420046]
25. Nowak JA, Forouzandeh B, Nowak JA. Estimates of Heli-cobacter pylori densities in the gastric mucus layer by PCR, histologic examination, and CLOtest. Am J Clin Pathol 1997; 108: 284-288 [PMID: 9291456]
26. Perez-Trallero E, Montes M, Alcorta M, Zubillaga P, Telleria E. Non-endoscopic method to obtain Helicobacter pylori for culture. Lancet 1995; 345: 622-623 [PMID: 7898181 DOI: 10.1016/S0140-6736(95)90524-3]
27. Wang SW, Yu FJ, Lo YC, Yang YC, Wu MT, Wu IC, Lee YC, Jan CM, Wang WM, Wu DC. The clinical utility of string-PCR test in diagnosing Helicobacter pylori infection. Hepato-gastroenterology 2003; 50: 1208-1213 [PMID: 14571700]
28. Yoshida H, Hirota K, Shiratori Y, Nihei T, Amano S, Yo-shida A, Kawamata O, Omata M. Use of a gastric juice-based PCR assay to detect Helicobacter pylori infection in culture-negative patients. J Clin Microbiol 1998; 36: 317-320 [PMID: 9431979]
29. Wang WM, Lee SC, Ding HJ, Jan CM, Chen LT, Wu DC, Liu CS, Peng CF, Chen YW, Huang YF, Chen CY. Quantification of Helicobacter pylori infection: Simple and rapid 13C-urea breath test in Taiwan. J Gastroenterol 1998; 33: 330-335 [PMID: 9658310 DOI: 10.1007/s005350050092]
30. Wu JY, Kim JJ, Reddy R, Wang WM, Graham DY, Kwon DH. Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob Agents Chemother 2005; 49: 578-583 [PMID: 15673736 DOI: 10.1128/AAC.49.2.578-583.2005]
31. Yang JC, Wang TH, Wang HJ, Kuo CH, Wang JT, Wang WC. Genetic analysis of the cytotoxin-associated gene and the vacuolating toxin gene in Helicobacter pylori strains isolated from Taiwanese patients. Am J Gastroenterol 1997; 92: 1316-1321 [PMID: 9260797]
32. Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries. J Clin Microbiol 1999; 37: 2274-2279 [PMID: 10364597]
33. Wang G, Taylor DE. Site-specifc mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimi-crob Agents Chemother 1998; 42: 1952-1958 [PMID: 9687389]
34. Yamaoka Y, Osato MS, Sepulveda AR, Gutierrez O, Figura N, Kim JG, Kodama T, Kashima K, Graham DY. Molecular epidemiology of Helicobacter pylori: separation of H. pylori from East Asian and non-Asian countries. Epidemiol Infect 2000; 124: 91-96 [PMID: 10722135 DOI: 10.1017/ S0950268899003209]
35. Lu H, Wu JY, Kudo T, Ohno T, Graham DY, Yamaoka Y. Regulation of interleukin-6 promoter activation in gastric epithelial cells infected with Helicobacter pylori. Mol Biol Cell 2005; 16: 4954-4966 [PMID: 16030249 DOI: 10.1091/mbc. E05-05-0426]
36. Delaney BC, Qume M, Moayyedi P, Logan RF, Ford AC, Elliott C, McNulty C, Wilson S, Hobbs FD. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008; 336: 651-654 [PMID: 18310262 DOI: 10.1136/bmj.39479.640486. AE]
37. Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm RK, Tanaka SK, Graham DY, Go MF. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-480 [PMID: 8834903]
38. Taylor DE. Pathophysiology of antibiotic resistance: clar-ithromycin. Can J Gastroenterol 2000; 14: 891-894 [PMID: 11188799]
39. Liou JM, Chang CY, Sheng WH, Wang YC, Chen MJ, Lee YC, Hung HW, Chian H, Chang SC, Wu MS, Lin JT. Geno-typic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofoxacin-and clarithromycin-based therapies. Antimicrob Agents Che-mother 2011; 55: 1123-1129 [PMID: 21189342 DOI: 10.1128/ AAC.01131-10]
40. Liu G, Xu X, He L, Ding Z, Gu Y, Zhang J, Zhou L. Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children. Helicobacter 2011; 16: 356-362 [PMID: 21923681 DOI: 10.1111/j.1523-5378.2011.00856.x]
41. Herrera PM, Mendez M, Velapatiño B, Santivañez L, Balqui J, Finger SA, Sherman J, Zimic M, Cabrera L, Watanabe J, Rodríguez C, Gilman RH, Berg DE. DNA-level diversity and relatedness of Helicobacter pylori strains in shantytown families in Peru and transmission in a developing-country setting. J Clin Microbiol 2008; 46: 3912-3918 [PMID: 18842944 DOI: 10.1128/JCM.01453-08]
42. Goncalves MH, Silva CI, Braga-Neto MB, Fialho AB, Fialho AM, Queiroz DM, Braga LL. Helicobacter pylori virulence genes detected by string PCR in children from an urban community in northeastern Brazil. J Clin Microbiol 2013; 51: 988-989 [PMID: 23254125 DOI: 10.1128/JCM.02583-12]
43. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-213 [PMID: 23158886 DOI: 10.1016/S0140-6736(12)61579-7]
44. Rimbara E, Noguchi N, Kijima H, Yamaguchi T, Kawai T, Sasatsu M. Mutations in the 23S rRNA gene of clarithromy-cin-resistant Helicobacter pylori from Japan. Int J Antimicrob Agents 2007; 30: 250-254 [PMID: 17590317 DOI: 10.1016/j.ijan-timicag.2007.04.009]